Genomatica today revealed that major nylon intermediates are the focus of its third publicly-disclosed development program. The aim of the nylon intermediates program is to deliver biobased processes for the production of the nylon building blocks hexamethylenediamine, caprolactam and adipic acid (HMD, CPL and ADA). These three chemicals, with a total market of over $18 billion per year, are used primarily in the production PA 6 and PA 6,6. The company is developing complete process technologies for the biobased production of all three intermediates, which it will then license to major firms in the nylon value chain.
This third program follows the successful commercialization and licensing of the company's GENO BDO process - among others, to BASF, that produced its first commercial volumes of bio1,4-butanediol (BDO) based on Genomatica's process last year November - and the major strides taken in its butadiene program, which has gained over $100 million in industry support, with Versalis and Braskem as anchor partners. These agreements with Braskem and Versalis provide a commercialization path in all major butadiene-producing and consuming regions of the world. Genomatica is planning a similar approach in its nylon intermediates program. The company is inviting leaders in the nylon value chain to join as development partners, who will have the opportunity to engage throughout the program, influence priorities and gain early access to the resulting process technology. Genomatica believes that such access can provide important time-to-market and competitive advantage to program sponsors.